Status:
NO_LONGER_AVAILABLE
Compassionate Use: Progressive Metastatic Castrate Resistant Prostate Cancer; Monotherapy Treatment With Trametinib
Lead Sponsor:
Jonsson Comprehensive Cancer Center
Collaborating Sponsors:
Novartis
Conditions:
Progressive Metastatic Castrate Resistant Prostate Cancer
Eligibility:
MALE
18+ years
Brief Summary
The dosage of trametinib for oral administration is 2mg once daily. The patient is instructed to take the trametinib oncedaily dose at approximately the same time each day, by mouth with approximately...
Detailed Description
The dosage of trametinib for oral administration is 2mg once daily. The patient is instructed to take the trametinib once daily dose at approximately the same time each day, by mouth with approximatel...
Eligibility Criteria
Inclusion
- Progressive Metastatic Castrate Resistant Prostate Cancer
Exclusion
- Absence of Progressive Metastatic Castrate Resistant Prostate Cancer
Key Trial Info
Start Date :
Trial Type :
EXPANDED_ACCESS
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT03386071
Last Update
January 16 2019
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.